Editorial
Copyright ©The Author(s) 2021.
World J Clin Oncol. Jan 24, 2021; 12(1): 6-12
Published online Jan 24, 2021. doi: 10.5306/wjco.v12.i1.6
Table 1 Metastasis-free survival in patients with nonmetastatic castration-resistant prostate cancer in the SPARTAN, PROSPER, and ARAMIS randomized controlled trials
Objective: MFS
n
HR for MFS
95%CI; P value
Apalutamide vs placebo (SPARTAN)12070.280.23-0.35; < 0.0001
Enzalutamide vs placebo (PROSPER)14010.290.24-0.35; < 0.0001
Darolutamide vs placebo (ARAMIS)15090.410.34-0.50; < 0.001